Drug Type Small molecule drug |
Synonyms erythro-nordihydroguaiaretic acid, Masoprocol (USAN/INN), meso-1,4-bis(3,4-dihydroxyphenyl)-2,3-dimethylbutane + [15] |
Target |
Mechanism 5-LOX inhibitors(Arachidonate 5-lipoxygenase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (04 Sep 1992), |
Regulation- |
Molecular FormulaC18H22O4 |
InChIKeyHCZKYJDFEPMADG-TXEJJXNPSA-N |
CAS Registry27686-84-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04862 | Masoprocol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Actinic Keratosis | US | 04 Sep 1992 |
Phase 2 | 12 | Nordihydroguaiaretic Acid (NDGA) | stngpmzsxx(yqifbsfkzc) = xbglchrjst btxzhwuhdm (vfhsupadfg, arlcwowkiw - rxiplthzuz) View more | - | 09 Apr 2014 | ||
Phase 2 | 12 | usfgtzcmcn(fmrxsoqwok) = xsbarbxgge yharosjkct (rycuuexkkt ) View more | - | 01 Jan 2012 | |||
Phase 2 | - | 28 | iyoicjwbfw(qmnuehkdck) = All grade 3 events occurred in 1 patient and included nausea/vomiting, cognitive disturbance, syncope due to dehydration, and elevated liver function tests umsxeoqpjh (ttveddunhf ) | - | 20 May 2010 |